Physician profile
Don-Andre Jackson
NPI 1508250952
$14,518.95
in general payments reported to CMS, 2019-2025
25 companies · $5,924 in 2025
The $5,924 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $2,348 · 2023: $2,134 · 2024: $3,581 · 2025: $5,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,064 · Consulting Fee: $5,293 · Education: $259 · Travel and Lodging: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,063.81 |
| Consulting Fee | $5,292.50 |
| Education | $258.98 |
| Travel and Lodging | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,962.43 | 2021-2025 | |
| Janssen Biotech, INC. | $3,432.31 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,825.65 | 2021-2025 | |
| Amgen INC. | $975.95 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $927.29 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $622.77 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $558.20 | 2022-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $279.90 | 2022-2024 | Benlysta |
| Pfizer INC. | $269.67 | 2021-2024 | |
| Horizon Therapeutics Plc | $205.77 | 2022-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $177.02 | 2022-2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $161.26 | 2023-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.47 | 2022-2024 | Cyltezo, Ofev |
| Kiniksa Pharmaceuticals International, Plc | $143.42 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $132.70 | 2023-2024 | Idacio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $123.71 | 2022 | |
| Ani Pharmaceuticals, INC. | $103.28 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $101.25 | 2023-2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $96.94 | 2023 | Arcalyst |
| Sandoz INC. | $79.78 | 2024-2025 | Hyrimoz, Jubbonti |
| E.R. Squibb & Sons, L.L.C. | $71.74 | 2024-2025 | Orencia |
| Organon LLC | $44.31 | 2024-2025 | Hadlima |
| Actelion Pharmaceuticals US, INC. | $32.03 | 2024 | Opsumit, Uptravi |
| Depuy Synthes Sales INC. | $20.53 | 2023 | Monovisc |
| Alexion Pharmaceuticals, INC. | $14.57 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don-Andre Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.